Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

Pfizer's 7.45% dividend yield can't offset weak growth, declining EPS, and patent risks. Read more on PFE and why analysts ...

On May 21, analyst Geoff Meacham of Citi maintained a Hold rating on Pfizer Inc. (NYSE:PFE), reiterating the price target of ...

Estimates for Pfizer’s 2025 earnings have risen from $2.97 to $2.98 per share over the past 30 days. (Find the latest earnings estimates and surprises on Zacks Earnings Calendar.) The healthcare ...

Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Pfizer (PFE) has been the focus of several analyst reports recently, with mixed ratings ...

saw its stock rise by 3.75% in pre-market trading, reflecting investor optimism about its earnings performance and strategic initiatives. Want deeper insights? InvestingPro analysis reveals 10+ ...

We recently published a list of 10 Stocks Market Experts are Talking About These Days. In this article, we are going to take a look at where Pfizer Inc (NYSE:PFE) stands against other stocks that ...

With that in mind, let's consider two high-yield dividend stocks worth investing in: Pfizer (NYSE: PFE) and Medical ...

Pfizer’s profits comfortably beat analyst predictions, despite lingering skepticism from cautious market observers. The dividend remains especially attractive, offering an enticing yield over 7%, a ...